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In continuing our search for effective local agents against pyogenic infections 
of the skin, we became interested in the new antibiotic, bacitracin. Here are 
reported the clinical results and the bacteriologic findings elicited in the study of 
165 patients treated with bacitracin in an ointment base. 
Johnson, Anker and Meleney (1) reported the discovery of bacitracin in "Science," 
October 12, 1945. They found it to be produced by a gram-positive, sporulating bacillus 
of the B. subtilis group. Their studies showed that bacitracin was neutral, water-soluble, 
non-toxic and relatively heat-stable. As a method of measurement, they arbitrarily set 
the "unit" as: "The amount which, when diluted 1:1024 in a series of 2-fold dilutions in 2 
cc. of beef infusion broth, completely inhibits the growth of a stock strain of Group A hemo-
lytic streptococcus when the inoculum used to seed the tubes is a 0.1 cc. of a 10--2 dilution of 
an overnight culture in blood broth." 
Scudi and Antopol (2) studied in rats and mice the toxicity of the then available prepara-
tions of bacitracin. They found evidence of damage to renal tubules following large intra-
peritoneal doses in mice, whereas in rats there was little kidney involvement. They estab-
lished the fact that lethal results were produced only by immense oral doses and that the 
subcutaneous LD6o in mice was 4 to 7 times the intraperitoneal LD5o. Scudi, Clift and 
Kreuger (3) studied the absorption and excretion of bacitracin in the dog. Since they were 
able to recover little bacitracin from the feces, and none from the blood and urine, after oral 
administration, they concluded that the antibiotic was largely destroyed in the gastrointes-
tinal tract. They gave intravenous doses as high as 6,000 units per kilogram of body weight 
without producing any apparent serious toxicity. They found that the bacitracin did not 
penetrate the red blood cells nor did it enter the spinal fluid freely. Using monkeys, Scudi, 
Coret and Antopol (4) i:Qjected 1500 units of commercial bacitracin per kilogram of body 
weight into the same area twice a day for 45 days. They found no evidence of significant 
changes in blood morphology, but albumin and sugar did appear in the urine of the animals 
during the test. At autopsy, histological evidence of kidney damage was minimal. They 
instilled 1200 units of bacitracin into the conjunctival sac of rabbits without producing any 
reaction. 
Meleney and Johnson (5), in March of 1947, reported an 88 per cent favorable response in 
the local treatment of 100 cases of surgical infections. They treated 57 cases, such as furun-
cles, carbuncles and abscesses, by injecting an aqueous solution of bacitracin directly into 
the lesion. They treated 32 patients with bacitracin in an ointment base and the remaining 
11 patients with both the solution and the ointment. 
In general it may be stated that bacitracin is effective in vitro against gram-
positive organisms both aerobic (streptococci, pneumococci, staphylococci, 
micrococci and corynebacteria) and anaerobic (clostridia, streptococci and micro-
*We are deeply indebted to Dr. FrankL. Meleney for many helpful suggestions. 
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cocci) and ineffective against gram-negative organisms (bacilli of the coliform, 
proteus and pyocyaneous groups) with the exception of the gonococcus and the 
meningococcus which are susceptible to its action. Fungi, such as monilia 
and crytococci, are resistant. Spirochetes are highly susceptible. 
PROCEDURE 
All of our cases were treated with an ointment containing 480 units per gram. 
Trial of ointments containing 100 units per gram gave uncertain results, and the 
figure of 480 units was arbitrarily selected. The experience of one of us (J. L. M.) 
(6) with penicillin would suggest that this concentration is sufficient and less 
likely to cause sensitization than higher strengths. 
The ointment base is the same as that described by Meleney and Johnson (5). It is made 
up with 45 parts of Carbo wax 4000 and 55 parts of propylene glycol. These substances are 
heated over a free flame until well mixed and then sterilized by dry heat at 140°C. for two 
hours. This base may be kept soft in the incubator and the bacitracin added when desired. 
When kept in the icebox, the ointment thus prepared remains potent for about six months, 
retaining full activity for as long as two months. At room temperature the ointment loses 
50 per cent of its potency in one week. Crude bacitracin for incorporation into the ointment 
is available commercially. It remains stable in aqueous solution at 5°C. for eight to twelve 
months. Bacitracin may be lyophilized and in this dried state in vacuum vials remains 
stable indefinitely at room temperatures. The ointment used melts at body temperature 
and since bacitracin is water soluble, the antibiotic is brought into close contact with the 
offending organism. A few patients have complained of a burning sensation following appli-
cation of this ointment. One of us (J. L. M.) (6) has eliminated this complaint when work-
ing with other substances in similar ointment bases by reducing the proportion of propylene 
glycol. Ointments of suitable consistency can be prepared, as described by Hopkins (7), 
hv using combinations of the softer Carbo wax 1500 with the harder Carbowax 4000 and less 
propylene glycol than we have used. 
The majority of our cases were ambulatory and were seen in the out-patient 
department. Cultures were taken in all cases to identify the responsible organ-
isms and to test their sensitivity to bacitracin. In stubborn cases, repeated 
cultures were made for evidence of the development while under treatment 
of bacitracin-resistant strains. As yet, the dividing point at which to classify 
an organism as bacitracin-sensitive or bacitracin-resistant for the purposes of 
local therapy has not been determined. In this series of cases, no staphylococcus 
was found resistant to more than 5 units per cc. of bacitracin, although staphylo-
cocci resistant to 100 units per cc. of penicillin were found. The hemolytic 
streptococci were all sensitive to 0.008 units or less of bacitracin except for cer-
tain strains of hemolytic enterococci which required as high as 0.01 units per cc. 
These differences in the sensitivities of the individual strains to bacitracin did 
not apparently influence the clinical results. 
The necessity for removal of crusts in superficial pyodermas is obvious. Our 
patients were instructed to use hot compresses of normal saline solution twice 
per day followed by application of the ointment. Hot compresses remove crusts 
painlessly and avoid the irritation frequently seen when soap and water are used 
for this purpose. In children particularly, this may mean the difference between 
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success and failure. Oxidizing agents, such as hydrogen peroxide and potassium 
permanganate, inactivate bacitracin and should not be used. 
RESULTS 
Table 1 shows that of 45 cases of impetigo treated, 26 were followed ade-
quately. Our standard of adequate follow-up requires that patients be seen 
several weeks after supposed cure and after stopping all treatment. This largely 
explains the wide difference between the total number of cases treated and those 
listed as adequately studied. The median time of cure was 8 days. Two cases 
are listed as failures. One resulted from lack of cooperation by the patient and 
the second, although improved, changed to another medication. 
TABLE 1 
Results in treatment of primary superficial infections of the skin with bacitracin ointment 
CASES JlEAC- TIHE REQUIRED FOR 
TOTAL ADE- FAIL- TION TO CURE DIAGNOSIS CASES QUATELY CURES URES MEDICA-FOL-
LOWED TION Max. Min. Median 
--- ---- --- ------
Impetigo contagiosa .......... 45 26 24 2 0 15 3 8 
Ecthyma ..................... 25 13 13 0 0 30 9 14 
Folliculitis beard ............. 21 16 9 7 0 60 7 21 
Folliculi tis elsewhere ......... 13 8 7 1 0 65 6 19 
Infectious eczematoid derma-
titis ........................ 10 10 10 0 0 14 4 7 
Vesiculopustular eruption of 
hands ...................... 7 6 3 3 1 25 14 21 
Furunculosis ............. . .... 3 2 2 0 0 23 12 17 
Pustular psoriasis ............. 2 2 0 2 0 
Acne varioliformis ............ 2 2 2 0 0 21 7 14 
Perifolliculitis abscedens et 
suffodiens .................. 2 2 0 2 0 
------
---
---------
Total. ......... . ...... . ..... 130 87 70 17 1 
Thirteen cases of ecthyma cleared in a median time of 14 days, with no failures. 
The patients requiring 25 to 30 days to cure used the ointment only sporadically. 
Ten cases of infectious eczematoid dermatitis cleared in a median time of 7 
days, with no reactions. Five of these had been treated previously with peni-
cillin, sulfathiazole or ammoniated mercury ointments. 
Clinical and bacteriologic differentiation between simple folliculitis of the 
beard and the very resistant cases of sycosis vulgaris is almost impossible except 
on the basis of duration of the infection. In this series of 16 cases, 13 had had 
their infection from one to seven years. Of the 5 cases cured, 3 had had the 
folliculitis only a few weeks. The remaining 2 listed a,s cured were of long 
duration and may recur, but to date have remained clear. Four cases have kept 
the infection under control by continued use of the ointment. Seven cases were 
failures. 
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Under vesiculo-pustular eruptions of the hands are listed patients who had had 
their complaint from 6 months to 12 years, in all of whom repeated cultures for 
fungi had been negative. The 3 cases listed as "cured" have been followed for 
two months with no sign of recurrence; one of these was of 12 years duration. 
Our only patient to react with a dermatitis was in this group. 
The 2 patients with perifolliculitis abscedens et suffodiens are listed as failures 
although all secondary infection was controlled and the patients were comfort-
able, requiring less frequent drainage of abscesses. 
Treatment of 2 cases of pustular psoriasis resulted in failure. 
In the group of various dermatoses with secondary infection listed in table 2, 
bacitracin ointment cured the secondary infection in all cases but proved of no 
value against the primary dermatosis. No evidence of sensitization was found 
TABLE 2 
Results in treatment of secondary infection in various dermatoses 
CASES 
TOTAL ADE- J!EACTION 
tTI<E J!EQUnED FOR CUJ!E 
SECONDARY INFECTION IN CASES QUATELY CUJ!ES FAILURES TO MEDI-FOL- CATION 
LOWED Max. Min. Median 
----- ------- --- ----
All~rgic eczema ............... 11 6 6 0 0 20 7 10 
Scabies ....................... 8 5 5 0 0 21 10 16 
Contact dermatitis ........... 7 4 4 0 0 11 9 10 
Dermophytosis ............... 4 4 4 0 0 14 6 7 
Larva migrans ................ 1 1 1 0 0 6 
Neurodermatitis .............. 1 1 1 0 0 12 
Bromide ulcer ................ 1 1 1 0 0 11 
Epidermolysis bullosa ......... 1 1 1 0 0 7 
Dermatitis artefacta .......... 1 1 1 0 0 21 
------------------
Total secondary infection ... 35 24 24 
in this group. If tables 1 and 2 are combined, it will be seen that the total per-
centage of sensitivity found was 0.9 per cent. 
Reference to tables 3 and 4 shows that the B. hemolytic streptococcus is in 
general much more sensitive to bacitracin than the staphylococcus. In the case 
of mixed infections, only the sensitivity of the staphylococcus and/or the strepto-
coccus is listed. The organisms found in addition to the staphylococcus and 
the streptococcus were diphtheroids, micrococcus, C. welchii. B. subtilis, 
coagulase-negative staphylococcus, non-hemolytic streptococcus, coliform ba-
cilli, B. proteus and Ps. pyocyaneus. All gram-negative organisms, namely 
coliform, proteus and pyocyaneus, were found to be bacitracin resistant. Of the 
gram-positive organisms, all were sensitive except the members of the B. subtilis 
group which were always resistant, and some of the micrococci which varied in 
sensitivity. 
The clinical results in the cases due to pure staphylococcus, pure B. hemolytic 
streptococcus and mixed infections were tabulated to see if cases due to the more 
sensitive streptococcus healed more rapidly. In impetigo this was true. The 
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TABLE 3 
Bacteriologic studies showing the organisms obtained in culture and their sensitivity to 
bacitracin 
ORGANISM SENSII'IVITY TO BACITRACIN 
DISEASE Co~~ase Beta he- Coag. pos. postbve molytic staph. plus Mixed• Coag./Jos. Beta hem. strep., staphylo- strept<>- beta.liem. staph., fcc. 
coccus, coccus, strep., per- percentage bac. Ufcc. bac. 
percentage percentage cent age 
--- --- ---
---
Impetigo contagiosa . ........ 41 13 3 43 0.12-2.5 0 0 0003-0 0 011 
Impetigo cont. bullosa ..... .. 60 0 0 40 0.3 -1.25 
EcthyYna .. . . .......... ... .. . 17 22 33 28 0.09-1.5 0.0012-0 .006 
Folliculitis beard ....... ..... 28 3 12 57 0 .31-2.5 0.005 
Folliculitis elsewhere . .. . . . .. 20 10 10 60 0.16-2 .5 0.0012-0.004 
Infectious eczematoid derma-
titis . . .. ............ . . ... .. 50 0 12 38 0 .06-1.25 0.007 
Vesiculopustular eruption 
hands .. . ............... .. . 40 0 0 60 0.62-1.5 
Furunculosis ........... . .. ... 33.3 0 33.3 33 .3 0.3 -1.25 0.0015 
Pustular psoriasis .. . . . . . . .. . . 0 0 0 100 0.31 
Acne varioliformis . .. ..... .. . 0 0 0 100 
Folliculitis abscedens et suf-
fodiens .... ... .. .. . . .. . . .. . 0 0 0 100 
Total. .. . . . . . .... . .. ..... . . 30.8t 8.0t 12 .0t 49 .2t 
" Contains in addition to staphylococcus, and/ or Beta hemolytic streptococcus or-
ganisms such as B. subtilis, C . welchii, B. proteus, Ps. pyocyaneus, diphtheroids, coliform 
bacillus, micrococcus, and diplococcus. 
t Percentage of total cases studied. 
TABLE 4 
Bacteriologic studies showing the organisms obtained in culture and their sensitivity 
to bacitracin 
ORGANISIC SENSil'IVITY TO BACI RACIN 
DISEASE Coa~ase Beta he- Co~ pos . pos1tive molytic stap . plus Mixed• coag.m•· Beta. hem. strep., staphyl<>- strepto- beta. hem. percentage staph., fcc. Ufcc. bac. coccus, coccus, strep., bac. 
percentage percentage percentage 
---
---
Allergic eczema ....... . .. .... 22.2 11.1 44.4 22.2 0.06-1.25 0.0007-Q.0015 
Scabies . ................. .... 0 0 37 63 0.187-2.5 0.0012-Q.008 
Contact dermatitis .......... 25 0 50 25 0.25-Q.62 0.0007-Q.0025 
Dermophytosis .......... .... 50 0 25 25 0.18-1.5 0.0007-Q.042 
Larva migrans . .. .... .... .... 0 0 100 0 0.3 0.0007 
Dermatitis artefacta ......... 0 0 100 0 0.5 0.002 
Total for secondary infec-
tion . . . . . ...... ....... . .. 18 .5t 3.7t 44 .5t 33 .3t 
* Contains in addition to staphylococcus, and/ or Beta hemolytic streptococcus or-
ganisms such as B. subtilis, C . welchii, B. proteus, Ps. pyocyaneus, diphtheroids, coliform 
bacillus, micrococcus, and diplococcus. 
t Percentage of total cases studied. 
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TABLE 5 
Changes in sensitivity of coagulase positive staphylococcus to bacitracin shown by more than 
one culture from the same patient during treatment 
SENSITIVITY TO BACITRACIN 
CASE NUJ4BER ORGANIS>l DAYS TREATED 
UNITS PER CC. BAC. 
Coagulase pos. Coagulase~eg. 
159 Coag. pos. staph. 0 0.62 
8 0.75 
5 Coag. pos . staph. 0 1.5 
4 2.5 
12 Coag. pos. staph. 0 0.75 
3 0.3 
123 Coag. pos. staph. 0 0.'15 
6 0.75 
58 Coag. pos. staph. 0 0.62 
6 0.75 
56 0.62 
65 Coag. pos. staph. 0 0.3 
10 2.5 
131 Coag. pos. staph. 0 1.25 
7 0.75 
18 Coag. pos. staph. 0 0.37 
14 0.75 
97 Coag. pos. staph. 0 1.25 
8 2.5 
101 Coag. pos. staph. 0 0.75 
6 0.75 
99 Coag. pos. staph. plus hem. strep. 0 0.62 
2 5.0 
111 Coag. pos. staph. plus hem. strep. 0 0.75 
7 0.37 
38 0.75 
38 Coag. pos. staph. plus hem. strep. 0 0.5 
5 0.5 
12 0.62 
100 Coag. pos. staph. plus hem. strep. 0 0.37 
7 0.5 
TABLE ~ontinued 
SENSITIVITY TO BACirRACIN, 
CASENmlBD OltGANISll DAYS :ntEATED 
UNITS PElt CC. BAC. 
Coagulase pos. Coagulase neg. 
39 Coag. pos. staph. plus hem. strep. 0 0.5 
6 0.5 
124 Mixed* 0 0.75 
12 0.75 
15 1.25 
126 Mixed* 0 0.187 
14 0.6 
102 Mixed* 0 0.31 
7 0.31 
7 Mixed* 0 1.25 
7 0.62 
156 Mixed* 0 1.25 
6 1.25 
134 Mixed* 0 0.18 
7 0.75 
32 Mixed* 0 2.5 
7 5.0 
3 Mixed* 0 0.187 
56 0.16 
76 Mixed* 0 0.75 
7 1.25 
87 Mixed* 0 0.37 
2 0.2 
34 Mixed* 0 0.62 
2 0.62 
72 Mixed* 0 0.16 
22 0.09 
2 Mixed* 0 0.37 
6 0.37 
9 2.5 
157 Mixed* 0 0.37 
4 No staph. 
169 Mixed* 0 0.62 
6 0.75 
* Contains in addition to staphylococcus, and/or Beta hemolytic streptococcus organ-
isms such as B. subtilis, C. welchii, B. proteus, Ps. pyocyaneus, diphtheroids, coliform 
bacillus, micrococcus, and diplococcus. 
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median time of cure for cases due to pure streptococcus was one half that of cases 
due to pure staphylococcus, and one-third that of cases due to mixed infections. 
However, in ecthyma practically the reverse was true, the cases due to the strep-
tococcus requiring longer than those due to the staphylococcus. Attempts to 
correlate the degree of the sensitivity of the organism and the rapidity of clinical 
response proved futile, as some of our best clinical results occurred in cases due 
to less sensitive organisms. 
Table 5 was compiled to gather evidence of the development of 8trains resistant 
to bacitracin. Of thirty cases in which repeated cultures were studied, one 
strain of staphylococcus showed a three-fold increase, and two others an eight-
fold increase in resistance. Several others showed a two-fold increase. Other 
strains showed a decrease in resistance. A check of the clinical results in these 
cases revealed no lengthening of the time required for cure. 
Patch tests were performed in 7 4 of our cases two weeks to two months after 
using the bacitracin ointment. In many cases the site of the original dermatitis 
was used. In no instance, including our one case in which a dermatitis had 
occurred, was a positive patch test obtained. 
COMMENTS 
Bacitracin in this series has proved an effective agent against pyogenic in-
fections of the skin. In the primary pyogenic infections, such as impetigo, the 
median time of cure of 8 days is a little longer than that of 6 days found by one 
of us (J. L. M.) (8) using the sulfonamide ointments and subsequently penicillin 
ointment (6). In this small series we have been extremely careful to be certain 
of cure. In a larger series the median time of cure may more closely approach 
that found with the sulfonamides and penicillin ointment. 
The results in folliculitis of the beard are variable, as was to be expected. In 
cases of short duration excellent, in long standing cases of true sycosis vulgaris 
irregular but sufficiently encouraging to justify a trial of this antibiotic. 
In infectious eczematoid dermatitis and in certain vesiculopustular eruptions 
of the hands, the results were particularly encouraging. These are the cases 
where sensitization to the agent used, resulting in a contact dermatitis, is most 
likely to occur. In fact, the only patient in our series who did become sensitized 
was suffering from a vesiculopustular eruption of the hands. The same applies 
to the entire group of dermatoses with secondary infection as here, too, effective 
agents against bacterial infection with low sensitizing powers are desired. 
In general, organisms susceptible to penicillin are also susceptible to bacitracin. 
In the case of mixed infections caused by bacteria other than staphylococcus and 
streptococcus, the sensitivity or resistance of the bacteria to penicillin and baci-
tracin was determined. It was found that in the 68 cases caused by mixed in-
fections, 46.2 per cent of the cultures contained diphtheroids, 15.4 per cent non-
hemolytic streptococcus, 10.8 per cent B. subtilis, 9.2 per cent C. welchii, 6.2 
per cent B. proteus and smaller percentages of other organisms. Of the diph-
theroids 56.7 per cent were sensitive to both penicillin and bacitracin, 36.7 per 
cent were penicillin-resistant but bacitracin-sensitive, and 6.6 per cent were 
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resistant to both. One diplococcus culture was found to be bacitracin-resistant 
and penicillin-sensitive. 
In the case of penicillin there is evidence that two factors are responsible for 
resistance, one, a cell resistance either natural or acquired, and second, the pro-
duction of an enzyme, penicillinase by certain strains of staphylococci, micro-
cocci, gram-negative bacilli and aerobic sporulating bacilli. With bacitracin 
there is evidence of cell resistance both natural and acquired, but no evidence, 
as yet, of bacitracinase production. 
Bacitracin is capable of causing sensitization in patients with a resultant 
dermatitis, as proved by our one case. So far this has been minimal, less than 
one per cent. The negative patch tests even in areas of skin where bacitracin 
had previously been used, strengthens the belief that it is of low sensitizing ca-
pacity. Prolonged usage of any drug frequently leads to sensitization. How-
ever, we have used bacitracin continuously for as long as four months, with no 
sign of reaction. 
Penicillin, in the beginning, also caused little sensitization but as it was more 
widely used, both by systemic injection and by various means of local applica-
tion, the percentage of reaction increased. The sulfonamides in our early series 
(8) sensitized approximately five per cent of patients, and this figure has remained 
fairly constant (9). 
The use of both the sulfonamides and penicillin ointments is opposed by many 
dermatologists, today, because of their sensitizing capacity precluding the use of 
the medicament in serious illnesses in a significant number of cases. Onlytime 
will ten whether this objection will also apply to bacitracin. To date, only 130 
patients have been treated with bacitracin by systemic injection (10). As more 
highly purified preparations of this antibiotic become available more extensive 
parenteral use is planned. We have not had the opportunity to administer 
bacitracin internally to our one patient who reacted from local application, to see 
if dermatitis would again result. 
CONCLUSIONS 
1. Bacitracin ointment, 480 units per gram, is an effective agent against super-
ficial pyogenic infections. 
2. In impetigo, the median time of cure with bacitracin ointment of 8 days 
compares favorably with 6 days when penicillin or sulfonamide ointments were 
used. 
3. The bacitracin ointment used caused a contact type of dermatitis in less 
than 1 per cent of cases. Patch tests after treatment, even at sites of former 
dermatitis, were all negative. 
4. The effectiveness and low sensitizing potential or bacitracin suggest its 
trial in infectious eczematoid dermatitis, folliculitis, vesiculopustular eruptions 
of the hands, and in the secondary infections accompanying many dermatoses. 
5. In general, organisms known to be sensitive to penicillin were found to be 
sensitive to bactiracin. There was no significant correlation between sensitivity 
of the organism to bacitracin and clinical results. 
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6. Evidence of the development of bacitracin-resistant strains was found, but 
there was no evidence of the production of bacitracinase. 
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